Extended survivability of prostate cancer cells in the absence of trophic factors: Increased proliferation, evasion of apoptosis, and the role of apoptosis proteins

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3466-3479

  Tang, Dean G ^a,b,c   Li, Li ^c   Chopra, Dharam P ^a   Porter, Arthur T ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c Biomide Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CARRIER PROTEINS; CELL DIVISION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032146095     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Raff, M. C. Social controls on cell survival and cell death. Nature (Lond.), 356: 397-400, 1992.
2. Raff, M. C., Barres, B. A., Burne, J. F., Coles, H. S., Ishizaki, Y., and Jacobson, M. D. Programmed cell death and the control of cell survival: lessons from the nervous system. Science (Washington DC), 262: 695-700, 1993.
3. Denmead, S. R., Lin, X. S., and Isaacs, J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 251-256, 1996.
4. Tang, D. G., and Porter, A. T. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate, 32: 284-293, 1997.
5. McDonnell, T. J., Troncoso, P., Brisby, S. M., Logothetis, C. L., Chung, L. W. K., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
6. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Choplin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol., 143: 390-400, 1993.
7. + cells of human prostate cancer xenograft LuCaP 23 following castration. Int. J. Cancer, 65: 85-89, 1996.
8. Fuyuya, Y., Krajewski, S., Epstein, J. I., Reed, J. C., and Isaacs, J. T. Expression of Bcl-2 and progression of human and rodent prostatic cancers. Clin. Cancer Res., 2: 389-398, 1996.
9. McConkey, D. J., Greene, G., and Pettaway, C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res., 56: 5594-5599, 1996.
10. Berchem, G. J., Bossler, M., Sugars, L. Y., Voeller, H. J., Zeitlin, S., and Gelman, E. P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res., 55: 735-738, 1995.
11. Raffo, A. J., Perlman, H., Chen, M-W., Day, M. L., Stritman, J. S., and Buttyan, R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.
12. Isaacs, W. B., Carter, B. S., and Ewing, C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51: 4716-4720, 1991.
13. Eastman, J. A., Hall, S. J., Sehgal, Wang, I. J., Timme, T. L., Yang, G., Connell-Crowley, L., Elledge, S. J., Zhang, W-W., Harper, J-W., and Thompson, T. C. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res., 55: 5151-5155, 1995.
14. Yang, C., Cirielli, C., Capogrossi, M. C., and Passanti, A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res., 55: 4210-4213, 1995.
15. Sells, S. F., Muthukkumar, S., Maddiwar, N., Johnstone, R., Boghaert, E., Gillis, D., Liu, G., Nair, P., Monnig, S., Collini, P., Mattson, M. P., Sukhatme, V. P., Zimmer, S. G., Wood, D. P., Jr., McRoberts, J. W., Shi, Y., and Rangnekar, V. M. Expression and function of the leucine zipper protein par-4 in apoptosis. Mol. Cell. Biol., 17: 3823-3832, 1997.
16. Day, M. L., Foster, R. G., Day, K. C., Zhao, X., Humphrey, P., Zhang, S. H., and Dean, D. C. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway. J. Biol. Chem., 272: 8125-8128, 1997.
17. Hsing, A. Y., Kadomatsu, K., Bonham, M. J., and Daneilpour, D. Regulation of apoptosis induced by transforming growth factor-β1 in nontumorigenic and tumorigenic rat prostatic epithelial cell lines. Cancer Res., 56: 5146-5149, 1996.
18. Sensibar, J. A., Sutkowski, D. M., Raffo, A., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowski, J. M., and Lee, C. Prevention of cell death induced by tumor necrosis factor a in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res., 55: 2431-2437, 1995.
19. Rokhlin, O. W., Bishop, G. A., Hostager, B. S., Waldschmidt, T. J., Sidorenko, S. P., Pavloff, N., Kiefer, M. C., Umanski, S. R., Glover, R. A., and Cohen, M. B. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res., 57: 1758-1768, 1997.
20. Borner, M. M., Myers, C. E., Sartor, O., Sei, Y., Toko, T., Trepel, J. B., and Schneider, E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res., 55: 2122-2128, 1995.
21. Sinha, B. K., Yamazaki, H., Eliot, H., Schneider, E., Borner, M. M., and O'Connor, P. M. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. Biochim. Biophys. Acta, 1270: 12-18, 1995.
22. Vukanovic, J., and Isaacs, J. T. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent Linomide. Cancer Res., 55: 3517-3520, 1995.
23. Li, C. J., Wang, C., and Pardee, A. B. Induction of apoptosis by β-lapachone in human prostate cancer cells. Cancer Res., 55: 3712-3715, 1995.
24. Planchon, S. M., Wuerzberger, S., Frydman, B., Witiak, D. T., Hutson, P., Church, D. P., Wilding, G., and Boothman, D. A. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res., 55: 3706-3711, 1995.
25. Carducci, M. A., Nelson, J. B., Chan-Tack, K. M., Ayyagari, S. R., Sweatt, W. H., Campbell, P. A., Nelson, W. G., and Simons, J. W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2: 379-387, 1996.
26. Wright, P. S., Cross-Doersen, D., Th'ng, J. P. H., Guo, X-W., Crissman, H. A., Bradbury, E. M., Montgomery, L. R., Thompson, E. Y., Loudy, D. E., Johnston, J. O., and Bitoni, A. J. A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exp. Cell Res., 222: 54-60, 1996.
27. Robertson, C. N., Robertson, K. M., Padilla, G. M., O'Brien, E. T., Cook, J. M., Kim, C-S., and Fine, R. L. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J. Natl. Cancer Inst., 88: 908-917, 1996.
28. Grove, K. L., and Cheng, Y-C. Uptake and metabolism of the new anticancer compound β-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res., 56: 4187-4191, 1996.
29. Robertson, K. M., Penland, S. N., Padilla, G. M., Selvan, R. S., Kim, C-S., Fine, R. L., and Robertson, C. N. Fenretinide. Induction of apoptosis and endogenous transforming growth factor β in PC-3 prostate cancer cells. Cell Growth Differ., 8: 101-111, 1997.
30. Day, M. L., Zhao, X., Wu, S., Swanson, P. E., and Humphrey, P. A. Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells. Cell Growth Differ., 5: 735-741, 1994.
31. Powell, C. T., Brittis, N. J., Stec, D., Hug, H., Heston, W. D. W., and Fair, W. R. Persistent membrane translocation of protein kinase Ca during 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ., 7: 419-428, 1996.
32. Rusnak, J. M., and Lazo, J. S. Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. Exp. Cell Res., 224: 189-199, 1996.
33. Fuyuya, Y., Lundmo, P., Short, A. D., Gill, D. L., and Isaacs, J. T. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res., 54: 6167-6175, 1994.
34. Garde, S., Basrur, V., Finkelman, M., Li, L., Krishan, A., Ben-Josef, E., Haddad, M., Taylor, J. D., Porter, A. T., and Tang, D. G. Prostate secretory protein (PSP94) suppresses the growth of human androgen-independent prostate adenocarcinoma cells in vitro and in vivo by inducing apoptosis. Proc. Am. Soc. Clin. Oncol., 16: A1970, 1997.
35. Tang, D. G., Li, L., Zhu, Z., and Joshi, B. Apoptosis in the absence of cytochrome c accumulation in the cytosol. Biochem. Biophys. Res. Commun., 242: 380-384, 1998.
36. Tang, D. G., Li, L., Zhu, Z., Joshi, B., Johnson, C. R., Marnett, L. J., Honn, K. V., Crissman, J. D., timar, J., and Porter, A. T. BMD188, a novel hydroxamic acid compound, demonstrates potent anti-prostate cancer effects in vitro and in vivo: requirements for mitochondria, reactive oxygen species, and proteases, Pathol. Oncol. Res., in press, 1998.
37. Chopra, D. P., Grignon, D. J., Joiakim, A., Mathieu, P. A., Mohamed, A., Sakr, W. A., Powell, I. J., and Sarkar, F. H. Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia and primary prostate carcinoma. J. Cell Physiol., 169: 269-280, 1996.
38. Tang, D. G., Chen, Y. Q., and Honn, K. V. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc. Natl. Acad. Sci. USA, 93: 5241-5246, 1996.
39. Tang, D. G., and Honn, K. V. Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: role of 12-lipoxygenase in regulating tumor cell survival. J. Cell Physiol., 172: 155-170, 1997.
40. Mosman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
41. Tang, D. G., Chen, Y. Q., Newman, P. J., Shi, L., Gao, X., Diglio, C. A., and Honn, K. V. Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J. Biol. Chem., 268: 22882-22894, 1993.
42. Haldar, S., Jena, N., and Croce, C. M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4507-4511, 1995.
43. Haldar, S., Chintapalli, J., and Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.
44. Ras in Ras-induced apoptosis. J. Biol. Chem., 271: 2376-2379, 1996.
45. Blagoskonny, M. V., Schulte, T., Nguyen, P., Trepel, J., and Neckers, L. M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res., 56: 1851-1854, 1996.
46. Guan, R-J., Moss, S. P., Arber, N., Krajewski, S., Reed, J. C., and Holt, P. R. 30 Kd phosphorylated form of Bcl-2 protein in human colon. Oncogene, 12: 2605-2609, 1996.
47. Das, R., Reddy, E. P., Chatterjee, D., and Andrews, D. W. Identification of a novel Bcl-2 related gene, BRAG-1, in human glioma. Oncogene, 12: 947-951, 1996.
48. Kubbutat, M. H. G., and Vousden, K. H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol., 17: 460-468, 1997.
49. Culic, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Hittmair, A., Zhang, J., Thurnher, M., Bartsch, G., and Klocker, H. Regulation of prostatic growth and function by peptide growth factors. Prostate, 28: 392-405, 1996.
50. Ko, L. J., and Prives, C. P53: puzzle and paradigm. Genes Dev., 10: 1054-1072, 1996.
51. Levine, A. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
52. Attardi, L. D., Lowe, S. W., Brugarolas, J., and Jacks, T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J., 15: 3693-3701, 1996.
53. Gorospe, M., Cirielli, C., Wang, X., Seth, P., Capogrossi, M. C., and Holbrook, N. J. P21Waf-1/Cip1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene, 14: 929-935, 1997.
54. Polyak, K., Waldman, T., He, T-C., Kinzler, K. W., and Vogelstein, B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev., 10: 1945-1952, 1996.
55. Reed, J. C. Double identity for proteins of the Bcl-2 family. Nature (Lond.), 387: 773-776, 1997.
56. Hockenbery, D. M. Bcl-2, a novel regulator of cell death. BioEssays, 17: 631-638, 1995.
57. L protein content in HT29 cells. Oncogene, 13: 2631-2637, 1996.
58. Miyashita, T., Krajewski, S., Krajewski, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and box gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.